Literature DB >> 3863906

Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome.

H W Seyberth, W Rascher, H Schweer, P G Kühl, O Mehls, K Schärer.   

Abstract

A congenital hypokalemic tubular disorder is described with many features resembling Bartter syndrome. Additional features include prenatal onset with polyhydramnios and premature labor; failure to thrive; episodes of fever, vomiting, diarrhea, and renal electrolyte and water wastage; hypercalciuria; nephrocalcinosis; and osteopenia. Unlike Bartter syndrome, there is no defect in tubular reabsorption of chloride. Urinary levels of prostaglandin E2 and 7 alpha-hydroxy-5,11-diketotetranorprosta-1,16-dioic acid are selectively elevated, indicating marked stimulation of renal and systemic PGE2 production. Chronic suppression of PGE2 activity by indomethacin corrects most of the abnormalities, and there is an immediate decompensation of the disease on indomethacin withdrawal. We conclude that these preterm infants have a distinct variety of hypokalemic tubular disorders rather than a variant of Bartter syndrome, because renal and systemic hyperprostaglandinism ranks high in the pathogenic chain of events, and the suppression of PGE2 hyperactivity is associated with significant improvement in the development (and probably in the prognosis) of the affected children.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3863906     DOI: 10.1016/s0022-3476(85)80395-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  32 in total

1.  K(+)-dependent gating of K(ir)1.1 channels is linked to pH gating through a conformational change in the pore.

Authors:  U Schulte; S Weidemann; J Ludwig; J Ruppersberg; B Fakler
Journal:  J Physiol       Date:  2001-07-01       Impact factor: 5.182

2.  Novel molecular variants of the Na-K-2Cl cotransporter gene are responsible for antenatal Bartter syndrome.

Authors:  R Vargas-Poussou; D Feldmann; M Vollmer; M Konrad; L Kelly; L P van den Heuvel; L Tebourbi; M Brandis; L Karolyi; S C Hebert; H H Lemmink; G Deschênes; F Hildebrandt; H W Seyberth; L M Guay-Woodford; N V Knoers; C Antignac
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

Review 3.  Pathophysiology and clinical presentations of salt-losing tubulopathies.

Authors:  Hannsjörg W Seyberth
Journal:  Pediatr Nephrol       Date:  2015-07-16       Impact factor: 3.714

4.  Linkage of infantile Bartter syndrome with sensorineural deafness to chromosome 1p.

Authors:  T M Brennan; D Landau; H Shalev; F Lamb; B C Schutte; R Y Walder; A L Mark; R Carmi; V C Sheffield
Journal:  Am J Hum Genet       Date:  1998-02       Impact factor: 11.025

5.  Uncompensated polyuria in a mouse model of Bartter's syndrome.

Authors:  N Takahashi; D R Chernavvsky; R A Gomez; P Igarashi; H J Gitelman; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

6.  Ultrasound diagnosis of nephrocalcinosis in preterm infants.

Authors:  N Woolfield; R Haslam; G Le Quesne; H M Chambers; R Hogg; K Jureidini
Journal:  Arch Dis Child       Date:  1988-01       Impact factor: 3.791

Review 7.  Genetic kidney diseases in the pediatric population of southern Israel.

Authors:  Gal Finer; Hanna Shalev; Daniel Landau
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

Review 8.  Threading through the mizmaze of Bartter syndrome.

Authors:  Willem Proesmans
Journal:  Pediatr Nephrol       Date:  2006-05-16       Impact factor: 3.714

9.  Gitelman's syndrome is genetically distinct from other forms of Bartter's syndrome.

Authors:  L Károlyi; A Ziegler; M Pollak; M Fischbach; K H Grzeschik; M C Koch; H W Seyberth
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

10.  Analysis of claudin genes in pediatric patients with Bartter's syndrome.

Authors:  Yan-Hua Chen; Jen-Jar Lin; Beverly G Jeansonne; Rodney Tatum; Qun Lu
Journal:  Ann N Y Acad Sci       Date:  2009-05       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.